Warm congratulations to Libang Pharmaceutical for winning the "China Innovative Pharmaceutical Enterprise" award for three consecutive years

On December 17, the "2017 (10th) China Pharmaceutical Strategy Summit and China Pharmaceutical Industry and Commerce Joint Innovation Conference" jointly sponsored by China Pharmaceutical Industry Information Center, China Pharmaceutical Business Association, and Chongqing Biomedical Industrial Park was grandly opened in Chongqing. Nearly a thousand people from the Ministry of Industry and Information Technology, the National Health and Family Planning Commission, the State Food and Drug Administration, the Ministry of Commerce, the National Development and Reform Commission, industry associations, well-known experts and scholars in the pharmaceutical industry at home and abroad, and industry leaders participated in the event summit.

The theme of this year's summit is "linking medical industry and business, creating and sharing a new future", which is in line with the current national strategy of "Healthy China", focuses on the pharmaceutical industry pattern, development direction and path under the new situation, and connects the four major sectors of industry, learning, research and medicine. Channels, conduct in-depth exchanges and pragmatic discussions on hot spots of policies and regulations, market competition pattern, status quo and changes in various fields, and jointly promote the healthy development of the pharmaceutical industry.

At the summit, the "2017 China Pharmaceutical Industry Economic Operation Index" was also released, and the "2017 China Innovative Pharmaceutical Enterprises" list was also grandly announced. Xi'an Libang Pharmaceutical Co., Ltd. and other 20 companies won this honor. This is the third time that the company has won the list after 2015. It further demonstrates its strong innovation capabilities and R&D capabilities, and has established a good momentum of continuous, steady and rapid development. 

The winning of this award is the glorious fruit of the joint efforts of all Libang people, and it is also an encouragement and spur to the company. Facing the future, Libang will continue to uphold the mission of "advocating science and bringing health to all living beings", stay true to our original aspirations, forge ahead, continue to deepen management innovation and technological innovation, and make greater contributions to China's pharmaceutical industry and human health.

Selection basis:

"China's Innovative Pharmaceutical Enterprise" is jointly selected by the Ministry of Industry and Information Technology, China Medical Information Center, and China Pharmaceutical Industry Research Institute, and comprehensively evaluates 10 dimensions of the company's innovation, layout, potential, operation, and strategy.

The selection of "China's Innovative Pharmaceutical Enterprises" is a rigorous, scientific, and authoritative selection of innovation in my country's pharmaceutical industry, and it is also an important basis for adding points or quality grading references in drug bidding in some provinces.

Background introduction:

The China Pharmaceutical Strategy Summit has attracted many enterprises to share the latest innovations and innovative management practices. It plays an active role in promoting the integration of "industry, research, research and medicine" and the transformation of scientific and technological achievements, promoting technical cooperation and promoting the integration of industry and finance. Provide strategic consulting for enterprise transformation and upgrading, predict industry trends, and integrate professional high-end summits with insightful vision.